Cue Biopharma
63 hedge funds and large institutions have $43M invested in Cue Biopharma in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.72% less ownership
Funds ownership: 29.65% → 27.93% (-1.7%)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
Holders
63
Holding in Top 10
–
Calls
$207K
Puts
$103K
Top Buyers
| 1 | +$489K | |
| 2 | +$473K | |
| 3 | +$445K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$320K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$314K |
Top Sellers
| 1 | -$2.46M | |
| 2 | -$411K | |
| 3 | -$396K | |
| 4 |
BL
Bleichroeder LP
New York
|
-$379K |
| 5 |
Renaissance Technologies
New York
|
-$323K |